October 18, 2023 11:38pm

RARE closed down -$5.10 to $31.73 with a +$0.18 or +0.57% to $35.00 aftermarket indication

Aggregate (gross) proceed from offering is expected at $300 M and they need the cash especially with the dept load.

J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities and TD Cowen are acting as joint book-running managers for the offering.

RARE is expected to grant the underwriters of the offering pre-funded (?) warrants of 1,666,722 an option for a period of 30 days.


In addition, RARE has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,500,000 shares of Its common stock at the public offering price, less the underwriting discount.


The offering is a go ... but a big discount from $37.02 on 10/16.


RARE Stats pre offering:

52-week low of $32.01 and a high of $54.98

50-day moving average

Average volume (10 day) – 1.13 M shares

Outstanding shares: 71,49 M

Float: 62.64 M

Held by Insiders: 4.66%

Held by Institutions:  98.58

Shares of percentage (%) float: 5.75% <9/29>

Cash: 7.72 M

Total Debt: 25.73 M

Operating Cash Flow (ttm): -458.72 M


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.